阿斯特捷利康與其他製藥公司擴大研究合作關係
AstraZeneca and Other Pharma Firms Expand Research Partnerships
Updated at: September 30, 2026 at 03:50 AM
製藥產業正經歷一場深刻的轉型，從傳統、孤立的研究模式轉向「系統性創新」的協作時代。
The pharmaceutical industry is undergoing a profound transformation, moving away from traditional, isolated research models toward a collaborative era of 'systematic innovation.'
阿斯特捷利康（AstraZeneca）等大廠正引領這項變革，近期投入20億美元與Summit Therapeutics合作，以推進具有突破性的抗癌藥物ivonescimab的開發，即為一例。
Major players like AstraZeneca are leading this shift, exemplified by their recent $2 billion investment in Summit Therapeutics to advance ivonescimab, a groundbreaking cancer drug.
這項策略不僅是為了獲取個別藥物，更是為了取用強大的技術平台，例如人工智慧驅動的發現與先進的基因組學工具。
This strategy is not merely about acquiring individual medicines; it is about accessing powerful technological platforms, such as AI-driven discovery and advanced genomic tools.
阿斯特捷利康目前在其90%以上的創新小分子藥物研發管線中運用了人工智慧，禮來（Eli Lilly）與艾伯維（AbbVie）等巨頭也採取了類似的趨勢。
AstraZeneca now utilizes artificial intelligence in over 90% of its small molecule pipeline, a trend mirrored by giants like Eli Lilly and AbbVie.
這種「乘數效應」得到了全球製造基礎設施投入的強力支持，確保了突破性成果能有效地擴大規模。
This 'multiplier effect' is further supported by heavy investments in global manufacturing infrastructure, ensuring that breakthroughs can be scaled effectively.
隨著製藥龍頭將資金與尖端數位技術相結合，協作模式已成為降低開發風險，並解決從腫瘤學到慢性病管理等領域中，全球最複雜且未被滿足之醫療需求的主要途徑。
As pharmaceutical leaders pair capital with cutting-edge digital technology, the collaborative model has become the primary vehicle for mitigating development risks and addressing the world's most complex, unmet medical needs in areas ranging from oncology to chronic disease management.
